StreetAlpha.app
Home › Stocks › PRLD

Prelude Therapeutics Inc (PRLD)

Healthcare
$3.32
▼ −2.64%
LAST CLOSE · NOV 17

Prelude Therapeutics develops precision cancer medicines, including targeted protein degraders and antibody drug conjugates, for patients with underserved cancers. It last closed at $3.32 on Nov 17, down 2.64% on the day.

AI Auto Pilots
Is PRLD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$21.6M
+105.4% vs a year ago
Net income
−$53.3M
−247.1% margin
EPS (diluted)
−$0.59
Free cash flow
−$28.0M
−129.6% margin
Valuation
Market cap
$265.8M
80.1M shares
P/E
–
No P/E while losing money
Price to sales
12.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$23.4M
At Sep 30
Shareholder equity
$124.1M
Shares outstanding
80.1M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $7.0M$7.0MFY2024FY2025: $12.1M$12.1MFY2025

From PRLD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated PRLD in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 261.4% upside

Based on 1 analyst who set a price target on PRLD in the past 90 days. The average target is $12.00, with a high of $12.00 and a low of $12.00, compared with the last close of $3.32.

Low $12.00Avg $12.00High $12.00
Blue marker: last close $3.32
Highest target$12.00
Average target$12.00
Lowest target$12.00
Latest rating changes
JP MorganInitiated
Sep 17Buy$12
HC Wainwright & Co.Reiterated
Jul 29Buy$8
D. Boral CapitalInitiated
May 4Buy$9
DateFirmActionRatingPrice target
Sep 17JP MorganInitiatedBuy$12
Jul 29HC Wainwright & Co.ReiteratedBuy$8
May 4D. Boral CapitalInitiatedBuy$9
Loading…

Technical Analysis

PRLD · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 12% below its 20 day and 18% below its 50 day average. It is 24% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot S1 at $3.23, and the nearest resistance the Pivot at $3.36.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.0%/day
Key levels
$6.8352 week high+105.7%
$4.49100 day average+35.2%
$4.11200 day average+23.8%
$3.9250 day average+18.1%
$3.78Swing high (Oct 21)+13.9%
$3.7220 day average+12.0%
$3.45Pivot R1+3.9%
$3.36Pivot+1.2%
$3.32Last close
$3.23Pivot S1−2.7%
$3.18Swing low (Oct 16)−4.2%
$1.3052 week low−60.8%
Indicators
RSI (14)37.53Weak, oversold below 30Neutral
MACD-0.13Below its signal lineBearish
Stochastic12.6Near the bottom of its rangeOversold
ADX (14)17.2No clear trend
Williams %R-94.9Oversold below −80, overbought above −20Oversold
CCI (20)-130.0Oversold below −100, overbought above 100Oversold
Rate of change−12.2%Change over 10 sessionsBearish
ATR (14)$0.30Typical daily range, 9.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PRLD

What happened before

See how PRLD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PRLD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PRLD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PRLD in the last 90 days.

Loading…

See today’s whale options flow across the market →

PRLD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲52 buying vs 30 selling
  • ▲Held by funds +3.1 pts
  • ▲Funds holding +17
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9275+22.7%
In funds' top 1000–
Held by funds65.1%62.0%+3.1 pts
New / increased23 / 2934 / 25−11.9%
Reduced / sold out24 / 68 / 13+42.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PRLD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRLD is in one of them and how their past PRLD trades turned out.

PRLD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PRLD in an article yet. Here's the latest on the wider market.

About Prelude Therapeutics

Prelude Therapeutics is a precision oncology company based in Wilmington, Delaware. It discovers and develops cancer medicines, including small molecule inhibitors, protein degraders, and antibody drug conjugates, aimed at cancers with limited treatment options. Its pipeline targets driver mutations in blood cancers and solid tumors, such as a JAK2V617F inhibitor for myeloproliferative neoplasms and a KAT6A degrader for advanced breast cancer. The company serves cancer patients and is advancing its candidates through clinical trials.

Headquarters
Wilmington, DE